Benzinga | Jul 28, 2020 07:16AM EDT

CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review Of Safety Data

MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ --CytoSorbents Corporation(NASDAQ:CTSO), a critical care immunotherapy leader commercializing its CytoSorb(r)blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Data Monitoring Committee (DMC) of the REFRESH 2-AKI trial has completed a comprehensive favorable review of safety data from the study with a positive recommendation to resume the trial.